Descripción del proyecto
Un nuevo medicamento para tratar la aplasia medular
La quimioterapia convencional no es específica y afecta tanto a las células normales como a las cancerosas. Esto causa anemia que, en determinados casos, puede ser grave y dar lugar a aplasia: la incapacidad de la médula ósea de producir suficientes eritrocitos o leucocitos. La aplasia también afecta al sistema inmunitario, lo que aumenta la susceptibilidad de los pacientes frente a infecciones. Para abordar este problema médico, el proyecto financiado con fondos europeos ExitAplasia ha desarrollado un medicamento novedoso que facilita la rápida regeneración del aparato circulatorio tras la quimioterapia. Este nuevo medicamento reduce el tiempo de hospitalización y, por lo tanto, la posibilidad de contraer infecciones, lo que mejora el resultado clínico de los pacientes tratados con quimioterapia.
Objetivo
With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
75014 PARIS
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.